NCT04755075View on ClinicalTrials.gov

Surufatinib Hepatic Impairment Study

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

February 12, 2021

Primary Completion Date

October 11, 2021

Study Completion Date

October 11, 2021

Conditions
Hepatic Impairment
Interventions
DRUG

Surufatinib

Subjects to receive Surufatinib 250 mg on Day 1

DRUG

Surufatinib

Subjects to receive Surufatinib 250 mg on Day 1

Trial Locations (2)

32809

Orlando Clinical Research Center, Inc., Orlando

92780

Orange County Research Center, Tustin

All Listed Sponsors
lead

Hutchison Medipharma Limited

INDUSTRY

NCT04755075 - Surufatinib Hepatic Impairment Study | Biotech Hunter | Biotech Hunter